"Effect of Weekly GLP1 Agonist Treatment in double Diabetes"

PHASE3RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Double Diabetes
Interventions
DRUG

Insulin + semaglutide treatment

Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)

DRUG

Usual insulin treatment

Usual insulin treatment

BIOLOGICAL

Biological check-up

at D0, D90 and D180

Trial Locations (1)

21000

RECRUITING

Chu Dijon Bourgogne, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER